Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CFD | P00746 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | PPIA | P62937 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714625 | 0.87 | EPHX1 (0.77) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL6033584 | 0.83 | TP53 (0.75) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL10910476 | 0.81 | EPHX1 (0.63) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL25022818 | 0.79 | EPHX1 (0.61) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL4588571 | 0.79 | EPHX1 (0.61) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL3062841 | 0.79 | EPHX1 (0.61) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL969258 | 0.79 | SMN1; SMN2 (0.67) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL11634676 | 0.79 | EPHX1 (0.61) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL22560035 | 0.79 | EPHX1 (0.61) | EPHX1SMN1; SMN2TP53EPHX2GAA | |
| SCHEMBL7749740 | 0.79 | SMN1; SMN2 (0.66) | EPHX1SMN1; SMN2TP53EPHX2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| CN-108601764-A | Compounds and methods for enhanced degradation of target proteins | 阿尔维纳斯股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-108350062-A | Targeting proteins are degraded to weaken the relevant bad inflammatory reaction of adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-108137507-A | Proteolysis conditioning agent and relevant application method based on MDM2 | 阿尔维纳斯股份有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-20110190296-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| US-20110190369-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | US | disclosed |
| EP-2319843-A1 | Substituted pyrrole derivatives and their use as HMG-CO inhibitors | Ranbaxy Laboratories Limited (IN) | 2011-05-11 | — | — | EP | disclosed |
| US-7923467-B2 | Substituted pyrrole derivatives and their use as HMG-CO inhibitors | Ranbaxy Laboratories, Inc. (IN) | 2011-04-12 | — | — | US | disclosed |
| CN-101967117-A | Substituted pyrrole derivatives and their use as HMG-CO inhibitors | RANBAXY LAB LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| CN-1812983-A | Substituted pyrrole derivatives and their use as hmg-co inhibitors | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056602-A1 | Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | EPHX1 302/4885SMN1; SMN2 4660/4885TP53 4474/4885 |
| US-20110190369-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | EPHX1 302/4885SMN1; SMN2 4660/4885TP53 4474/4885 |
| US-20110190296-A1 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors | HMGCR, HMGB2, HMGB3 | EPHX1 302/4885SMN1; SMN2 4660/4885TP53 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.